Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nexna
- Development stage
- Unknown
- Lead developer
- Percos India
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Nexna is an oral nutritional supplement marketed by Percos India for the management of polycystic ovary syndrome (PCOS) and associated metabolic and reproductive symptoms, such as insulin resistance, acne, hirsutism, acanthosis nigricans, and skin tags. It is formulated as a combination tablet containing N-acetylcysteine (NAC), alpha-lipoic acid (ALA), inositol, chromium picolinate, and zinc gluconate. These ingredients work synergistically to improve insulin sensitivity, regulate hormonal balance, restore normal ovarian function, and reduce oxidative stress and inflammation.
- Brand names
- Nexna
- Other names
- Nexna Tabletacetylcysteine + alpha-lipoic acid + chromium picolinate + inositol + zinc gluconate
02
Targets
MUC2 (Mucin-2)GSH (Glutathione)
Beyond the preview
Go deeper on Nexna.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nexna.